Skip to content

Study · Animal study (in vivo) · rat · 2009

7 results

Gastric pentadecapeptide BPC 157 and short bowel syndrome in rats.

Sever M, Klicek R, Radic B, Brcic L, Zoricic I, Drmic D, Ivica M, Barisic I, Ilic S, Berkopic L, Blagaic AB, Coric M and 5 more

Show all authors

Kolenc D, Vrcic H, Anic T, Seiwerth S, Sikiric P

Digestive diseases and sciences18 Dec 2008Cited by 28 (Europe PMC)

PMID19093208 (opens in a new tab)DOI10.1007/s10620-008-0598-y (opens in a new tab)PepBankPUB-19093208
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with short bowel syndrome, BPC‑157 given perorally or parenterally gave constant weight gain above preoperative values.

    In plain wordsIn rats with short bowel syndrome, BPC‑157 led to steady weight gain above the weight before surgery.

    Peptide
    BPC-157
    Outcome
    IncreaseBody weight after small bowel resection
    Study

    ratn: not reported in source

    Short bowel syndrome after small bowel resection
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 microg/kg or 10 ng/kg · peroral (drinking water) or intraperitoneal · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    constant weight gain above preoperative values was observed immediately with BPC 157 therapy, both perorally and parenterally
    2 context sentences
    Summary · context
    Therefore, we studied for 4 weeks rats with escalating short bowel syndrome and progressive weight loss after small bowel resection from fourth ileal artery cranially of ileocecal valve to 5 cm beneath pylorus.
    Summary · context
    BPC 157 (10 microg/kg or 10 ng/kg) was given perorally, in drinking water (12 ml/rat/day) or intraperitoneally (once daily, first application 30 min following surgery, last 24 h before sacrifice).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with short bowel syndrome, BPC‑157 increased villus height at 7, 14, 21 and 28 days.

    In plain wordsIn rats with short bowel syndrome, BPC‑157 increased the height of the finger-like folds in the gut lining.

    Peptide
    BPC-157
    Outcome
    IncreaseVillus height
    Study

    ratn: not reported in source

    Short bowel syndrome after small bowel resection
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 microg/kg or 10 ng/kg · peroral (drinking water) or intraperitoneal · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    and villus height, crypt depth, and muscle thickness [inner (circular) muscular layer] also increased, at 7, 14, 21, and 28 days
    2 context sentences
    Summary · context
    Therefore, we studied for 4 weeks rats with escalating short bowel syndrome and progressive weight loss after small bowel resection from fourth ileal artery cranially of ileocecal valve to 5 cm beneath pylorus.
    Summary · context
    BPC 157 (10 microg/kg or 10 ng/kg) was given perorally, in drinking water (12 ml/rat/day) or intraperitoneally (once daily, first application 30 min following surgery, last 24 h before sacrifice).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with short bowel syndrome, BPC‑157 increased crypt depth at 7, 14, 21 and 28 days.

    In plain wordsIn rats with short bowel syndrome, BPC‑157 increased crypt depth in the gut lining.

    Peptide
    BPC-157
    Outcome
    IncreaseCrypt depth
    Study

    ratn: not reported in source

    Short bowel syndrome after small bowel resection
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 microg/kg or 10 ng/kg · peroral (drinking water) or intraperitoneal · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    and villus height, crypt depth, and muscle thickness [inner (circular) muscular layer] also increased, at 7, 14, 21, and 28 days
    2 context sentences
    Summary · context
    Therefore, we studied for 4 weeks rats with escalating short bowel syndrome and progressive weight loss after small bowel resection from fourth ileal artery cranially of ileocecal valve to 5 cm beneath pylorus.
    Summary · context
    BPC 157 (10 microg/kg or 10 ng/kg) was given perorally, in drinking water (12 ml/rat/day) or intraperitoneally (once daily, first application 30 min following surgery, last 24 h before sacrifice).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with short bowel syndrome, BPC‑157 increased muscle thickness of the inner circular muscular layer at 7, 14, 21 and 28 days.

    In plain wordsIn rats with short bowel syndrome, BPC‑157 increased the thickness of the gut muscle layer.

    Peptide
    BPC-157
    Outcome
    IncreaseInner (circular) muscle layer thickness
    Study

    ratn: not reported in source

    Short bowel syndrome after small bowel resection
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 microg/kg or 10 ng/kg · peroral (drinking water) or intraperitoneal · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    and villus height, crypt depth, and muscle thickness [inner (circular) muscular layer] also increased, at 7, 14, 21, and 28 days
    2 context sentences
    Summary · context
    Therefore, we studied for 4 weeks rats with escalating short bowel syndrome and progressive weight loss after small bowel resection from fourth ileal artery cranially of ileocecal valve to 5 cm beneath pylorus.
    Summary · context
    BPC 157 (10 microg/kg or 10 ng/kg) was given perorally, in drinking water (12 ml/rat/day) or intraperitoneally (once daily, first application 30 min following surgery, last 24 h before sacrifice).
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with short bowel syndrome, BPC‑157 treated rats showed jejunal and ileal diameters that were not different; the abstract does not name the comparison group.

    In plain wordsIn rats with short bowel syndrome, gut widths in BPC‑157 treated rats were reported as not different; the comparison is not stated.

    Peptide
    BPC-157
    Outcome
    No significant changeJejunal and ileal diameters
    Study

    ratn: not reported in source

    Short bowel syndrome after small bowel resection
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 microg/kg or 10 ng/kg · peroral (drinking water) or intraperitoneal · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    showed not different jejunal and ileal diameters, constant jejunum-to-ileum ratio, and increased anastomosis breaking strength.
    2 context sentences
    Summary · context
    Therefore, we studied for 4 weeks rats with escalating short bowel syndrome and progressive weight loss after small bowel resection from fourth ileal artery cranially of ileocecal valve to 5 cm beneath pylorus.
    Summary · context
    BPC 157 (10 microg/kg or 10 ng/kg) was given perorally, in drinking water (12 ml/rat/day) or intraperitoneally (once daily, first application 30 min following surgery, last 24 h before sacrifice).
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with short bowel syndrome, BPC‑157 treated rats showed a constant jejunum-to-ileum ratio.

    In plain wordsIn rats with short bowel syndrome, BPC‑157 treated rats kept a steady ratio between two gut sections.

    Peptide
    BPC-157
    Outcome
    No significant changeJejunum-to-ileum ratio
    Study

    ratn: not reported in source

    Short bowel syndrome after small bowel resection
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 microg/kg or 10 ng/kg · peroral (drinking water) or intraperitoneal · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    constant jejunum-to-ileum ratio
    2 context sentences
    Summary · context
    Therefore, we studied for 4 weeks rats with escalating short bowel syndrome and progressive weight loss after small bowel resection from fourth ileal artery cranially of ileocecal valve to 5 cm beneath pylorus.
    Summary · context
    BPC 157 (10 microg/kg or 10 ng/kg) was given perorally, in drinking water (12 ml/rat/day) or intraperitoneally (once daily, first application 30 min following surgery, last 24 h before sacrifice).
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats with short bowel syndrome, BPC‑157 treated rats had increased anastomosis breaking strength.

    In plain wordsIn rats with short bowel syndrome, BPC‑157 made the surgical join stronger.

    Peptide
    BPC-157
    Outcome
    IncreaseAnastomosis breaking strength
    Study

    ratn: not reported in source

    Short bowel syndrome after small bowel resection
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 microg/kg or 10 ng/kg · peroral (drinking water) or intraperitoneal · 4 weeksAs given in this study (rat).

    Source sentences

    Summary
    increased anastomosis breaking strength.
    2 context sentences
    Summary · context
    Therefore, we studied for 4 weeks rats with escalating short bowel syndrome and progressive weight loss after small bowel resection from fourth ileal artery cranially of ileocecal valve to 5 cm beneath pylorus.
    Summary · context
    BPC 157 (10 microg/kg or 10 ng/kg) was given perorally, in drinking water (12 ml/rat/day) or intraperitoneally (once daily, first application 30 min following surgery, last 24 h before sacrifice).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.